CVS Health Corporation $CVS Shares Sold by First Trust Advisors LP

First Trust Advisors LP reduced its holdings in shares of CVS Health Corporation (NYSE:CVS) by 18.7% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 2,351,094 shares of the pharmacy operator’s stock after selling 542,413 shares during the period. First Trust Advisors LP’s holdings in CVS Health were worth $177,249,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in CVS. Harbor Capital Advisors Inc. grew its stake in shares of CVS Health by 72.1% in the third quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock worth $26,000 after acquiring an additional 142 shares in the last quarter. Corundum Trust Company INC acquired a new stake in shares of CVS Health in the third quarter valued at $29,000. Front Row Advisors LLC boosted its holdings in CVS Health by 436.5% in the second quarter. Front Row Advisors LLC now owns 456 shares of the pharmacy operator’s stock valued at $31,000 after purchasing an additional 371 shares during the period. Twin Peaks Wealth Advisors LLC acquired a new position in CVS Health during the 2nd quarter worth $36,000. Finally, SOA Wealth Advisors LLC. increased its holdings in CVS Health by 36.9% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator’s stock worth $37,000 after purchasing an additional 131 shares during the period. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on CVS. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of CVS Health in a research report on Thursday, December 4th. Wolfe Research cut their target price on shares of CVS Health from $100.00 to $97.00 and set an “outperform” rating on the stock in a research note on Monday, March 2nd. Bank of America reduced their target price on shares of CVS Health from $100.00 to $95.00 and set a “buy” rating on the stock in a report on Tuesday, January 27th. Piper Sandler reiterated an “overweight” rating and set a $101.00 price target (up from $99.00) on shares of CVS Health in a report on Wednesday, December 10th. Finally, The Goldman Sachs Group increased their price objective on shares of CVS Health from $95.00 to $97.00 and gave the company a “buy” rating in a research report on Thursday, February 12th. Nineteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $94.91.

CVS Health Trading Down 1.0%

CVS opened at $77.91 on Friday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.63 and a current ratio of 0.84. CVS Health Corporation has a one year low of $58.35 and a one year high of $85.15. The company has a market cap of $99.12 billion, a P/E ratio of 56.46, a PEG ratio of 0.81 and a beta of 0.49. The business’s 50-day simple moving average is $78.49 and its 200-day simple moving average is $77.60.

CVS Health (NYSE:CVS) last posted its earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.09. The firm had revenue of $105.69 billion during the quarter, compared to analysts’ expectations of $103.67 billion. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The firm’s revenue was up 8.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.19 earnings per share. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. As a group, equities research analysts expect that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Thursday, January 22nd were issued a $0.665 dividend. The ex-dividend date was Thursday, January 22nd. This represents a $2.66 annualized dividend and a dividend yield of 3.4%. CVS Health’s dividend payout ratio is presently 192.75%.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS launched Health100, a new AI-native health‑tech subsidiary and consumer engagement platform built with Google Cloud. Management says the platform will unify data across payers, providers and pharmacies to drive personalized engagement and better outcomes — a potential long‑term revenue and margin lever if adoption scales. CVS taps Google Cloud to roll out AI-powered health platform
• Positive Sentiment: Broad media and trade coverage highlights the Google Cloud tie‑up and Health100 rollout, increasing visibility for CVS as a tech-enabled healthcare integrator — this can support multiple revenue streams (retail, PBM, value-based care) over time. CVS Health And Google Launch AI Business To ‘Personalize Healthcare’
• Positive Sentiment: Analyst and long‑term bulls point to margin recovery and FY2026 guidance (CVS set EPS guidance ~5.94–6.14) plus a recent quarterly beat — supporting the thesis that Medicare Advantage margin improvement and Health100 monetization could drive sizable upside over 12–24 months. CVS Health: Stop Catastrophizing, Start Believing – Here’s Why
• Neutral Sentiment: Market commentary questions whether recent gains already price in recovery — some pieces analyze valuation and one‑year returns, useful for timing but not a direct catalyst. Is CVS Health (CVS) Still Attractive After A 27% One Year Share Price Gain
• Negative Sentiment: Regulatory risk in Tennessee: a proposed bill would bar companies from owning both retail pharmacies and PBMs, and CVS warned it could close all 134 locations in the state if the law passes — an example of state‑level regulatory risks that could hit revenue, footprint and investor sentiment. CVS warns bill would force shutdown of 134 pharmacies in this state
• Negative Sentiment: Wolfe Research trimmed its price target on CVS, a modest negative for near‑term sentiment even though the firm remains focused on longer‑term fundamentals. Wolfe Research Cuts CVS Health (NYSE:CVS) Price Target to $97.00

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.